Evidence mapPaperPMID 40544162Full record

Articlenpj aging2025

Multinational evaluation of AnthropoAge as a measure of biological age in the USA, England, Mexico, Costa Rica, and China: a population-based longitudinal study.

Carlos A Fermín-Martínez, Daniel Ramírez-García, Neftali Eduardo Antonio-Villa, Jerónimo Perezalonso Espinosa, Diego Aguilar-Ramírez, Carmen García-Peña, Luis Miguel Gutiérrez-Robledo, Jacqueline A Seiglie, Omar Yaxmehen Bello-Chavolla

Abstract read
In one paragraph

Article in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Carlos A Fermín-MartínezResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico. carlosfermin38@gmail.com.
Daniel Ramírez-GarcíaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Neftali Eduardo Antonio-VillaDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Jerónimo Perezalonso EspinosaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Diego Aguilar-RamírezClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Carmen García-PeñaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Luis Miguel Gutiérrez-RobledoResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
Jacqueline A SeiglieDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
Omar Yaxmehen Bello-ChavollaResearch Division, Instituto Nacional de Geriatría, Mexico City, Mexico. oyaxbell@yahoo.com.mx.

Funding

Consejo Nacional de Humanidades, Ciencias y Tecnologías CBF2023-2024-467
6 · The paper itself

Abstract

We validated AnthropoAge, a biological age (BA) metric, for prediction of mortality and age-related outcomes using harmonized data from the US, England, Mexico, Costa Rica, and China. We estimated AnthropoAge and AnthropoAgeAccel as proxies of BA and age acceleration using body mass index and waist-to-height ratio. We compared mortality prediction of AnthropoAge vs. chronological age (CA) using Cox models and assessed its association with age-related outcomes with generalized estimating equations. Among 57,080 participants aged 50-94 years, AnthropoAgeAccel (c-statistic 0.806) improved mortality prediction of CA (0.803) and identified distinct aging trends for each country. Accelerated aging (AnthropoAgeAccel>0) increased mortality risk by ~37% independently of age and covariates, and predicted health deterioration, new deficits in activities of daily living, and age-related diseases. AnthropoAge is a robust BA metric with potential applications in identifying functional deficits, health decline, and mortality risk. However, it requires further validation and potential recalibration for broader applicability in underrepresented populations like Latin America.

Identifiers

PMID40544162
PMCPMC12182590

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.